Efferon is a biotech company specializing in the development of multimodal hemoadsorption therapeutic devices. Their core technology aims to remove endotoxins and inflammatory mediators directly from the bloodstream. The company's product portfolio includes Efferon LPS, a hemoadsorption cartridge for endotoxin and cytokine adsorption, and Efferon NEO, a version specifically designed for pediatric use. These devices are intended to support faster stabilization of septic shock, reduce time on mechanical ventilation, and decrease intensive care treatment costs. Efferon's platform is also being explored for future applications beyond acute critical illness, targeting chronic and age-related diseases. The company is committed to raising the profile of sepsis treatment globally.